Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients

Ji Yong Jang, Sang Hak Lee, Byung Soo Kim, Hong Seog Seo, Woo Shik Kim, Youngkeun Ahn, Nae Hee Lee, Kwang Kon Koh, Tae Soo Kang, Sang Ho Jo, Bum Kee Hong, Jang Ho Bae, Hyoung Mo Yang, Kwang Soo Cha, Bum Soo Kim, Choong Hwan Kwak, Deok Kyu Cho, Ung Kim, Joo Hee Zo, Duk Hyun KangWook Bum Pyun, Kook Jin Chun, June Namgung, Tae Joon Cha, Jae Hyeon Juhn, Yeili Jung, Yangsoo Jang

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background and Objectives: We compared the efficacy and safety of valsartan and rosuvastatin combination therapy with each treatment alone in hypercholesterolemic hypertensive patients. Subjects and Methods: Patients who met inclusion criteria were randomized to receive 1 of the following 2-month drug regimens: valsartan 160 mg plus rosuvastatin 20 mg, valsartan 160 mg plus placebo, or rosuvastatin 20 mg plus placebo. The primary efficacy variables were change in sitting diastolic blood pressure (sitDBP) and sitting systolic blood pressure (sitSBP), and percentage change in low-density lipoprotein-cholesterol (LDL-C) in the combination, valsartan, and rosuvastatin groups. Adverse events (AEs) during the study were analyzed. Results: A total of 354 patients were screened and 123 of them were finally randomized. Changes of sitDBP by least squares mean (LSM) were -11.1, -7.2, and -3.6 mm Hg, respectively, and was greater in the combination, as compared to both valsartan (p=0.02) and rosuvastatin (p<0.001). Changes of sitSBP by LSM were -13.2, -10.8, and -4.9 mm Hg, and was greater in the combination, as compared to rosuvastatin (p=0.006) and not valsartan (p=0.42). Percentage changes of LDL-C by LSM were -52, -4, and -47% in each group, and was greater in the combination, as compared to valsartan (p<0.001), similar to rosuvastatin (p=0.16). Most AEs were mild and resolved by the end of the study. Conclusion: Combination treatment with valsartan and rosuvastatin exhibited an additive blood pressure-lowering effect with acceptable tolerability, as compared to valsartan monotherapy. Its lipid lowering effect was similar to rosuvatatin monotherapy.

Original languageEnglish
Pages (from-to)225-233
Number of pages9
JournalKorean Circulation Journal
Volume45
Issue number3
DOIs
Publication statusPublished - 2015 May 1

Fingerprint

Valsartan
Blood Pressure
Least-Squares Analysis
Therapeutics
LDL Cholesterol
Placebos
Rosuvastatin Calcium

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Jang, Ji Yong ; Lee, Sang Hak ; Kim, Byung Soo ; Seo, Hong Seog ; Kim, Woo Shik ; Ahn, Youngkeun ; Lee, Nae Hee ; Koh, Kwang Kon ; Kang, Tae Soo ; Jo, Sang Ho ; Hong, Bum Kee ; Bae, Jang Ho ; Yang, Hyoung Mo ; Cha, Kwang Soo ; Kim, Bum Soo ; Kwak, Choong Hwan ; Cho, Deok Kyu ; Kim, Ung ; Zo, Joo Hee ; Kang, Duk Hyun ; Pyun, Wook Bum ; Chun, Kook Jin ; Namgung, June ; Cha, Tae Joon ; Juhn, Jae Hyeon ; Jung, Yeili ; Jang, Yangsoo. / Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients. In: Korean Circulation Journal. 2015 ; Vol. 45, No. 3. pp. 225-233.
@article{599032eec3d34206a63b8ecf5b47688a,
title = "Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients",
abstract = "Background and Objectives: We compared the efficacy and safety of valsartan and rosuvastatin combination therapy with each treatment alone in hypercholesterolemic hypertensive patients. Subjects and Methods: Patients who met inclusion criteria were randomized to receive 1 of the following 2-month drug regimens: valsartan 160 mg plus rosuvastatin 20 mg, valsartan 160 mg plus placebo, or rosuvastatin 20 mg plus placebo. The primary efficacy variables were change in sitting diastolic blood pressure (sitDBP) and sitting systolic blood pressure (sitSBP), and percentage change in low-density lipoprotein-cholesterol (LDL-C) in the combination, valsartan, and rosuvastatin groups. Adverse events (AEs) during the study were analyzed. Results: A total of 354 patients were screened and 123 of them were finally randomized. Changes of sitDBP by least squares mean (LSM) were -11.1, -7.2, and -3.6 mm Hg, respectively, and was greater in the combination, as compared to both valsartan (p=0.02) and rosuvastatin (p<0.001). Changes of sitSBP by LSM were -13.2, -10.8, and -4.9 mm Hg, and was greater in the combination, as compared to rosuvastatin (p=0.006) and not valsartan (p=0.42). Percentage changes of LDL-C by LSM were -52, -4, and -47{\%} in each group, and was greater in the combination, as compared to valsartan (p<0.001), similar to rosuvastatin (p=0.16). Most AEs were mild and resolved by the end of the study. Conclusion: Combination treatment with valsartan and rosuvastatin exhibited an additive blood pressure-lowering effect with acceptable tolerability, as compared to valsartan monotherapy. Its lipid lowering effect was similar to rosuvatatin monotherapy.",
author = "Jang, {Ji Yong} and Lee, {Sang Hak} and Kim, {Byung Soo} and Seo, {Hong Seog} and Kim, {Woo Shik} and Youngkeun Ahn and Lee, {Nae Hee} and Koh, {Kwang Kon} and Kang, {Tae Soo} and Jo, {Sang Ho} and Hong, {Bum Kee} and Bae, {Jang Ho} and Yang, {Hyoung Mo} and Cha, {Kwang Soo} and Kim, {Bum Soo} and Kwak, {Choong Hwan} and Cho, {Deok Kyu} and Ung Kim and Zo, {Joo Hee} and Kang, {Duk Hyun} and Pyun, {Wook Bum} and Chun, {Kook Jin} and June Namgung and Cha, {Tae Joon} and Juhn, {Jae Hyeon} and Yeili Jung and Yangsoo Jang",
year = "2015",
month = "5",
day = "1",
doi = "10.4070/kcj.2015.45.3.225",
language = "English",
volume = "45",
pages = "225--233",
journal = "Korean Circulation Journal",
issn = "1738-5520",
publisher = "Korean Society of Circulation",
number = "3",

}

Jang, JY, Lee, SH, Kim, BS, Seo, HS, Kim, WS, Ahn, Y, Lee, NH, Koh, KK, Kang, TS, Jo, SH, Hong, BK, Bae, JH, Yang, HM, Cha, KS, Kim, BS, Kwak, CH, Cho, DK, Kim, U, Zo, JH, Kang, DH, Pyun, WB, Chun, KJ, Namgung, J, Cha, TJ, Juhn, JH, Jung, Y & Jang, Y 2015, 'Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients', Korean Circulation Journal, vol. 45, no. 3, pp. 225-233. https://doi.org/10.4070/kcj.2015.45.3.225

Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients. / Jang, Ji Yong; Lee, Sang Hak; Kim, Byung Soo; Seo, Hong Seog; Kim, Woo Shik; Ahn, Youngkeun; Lee, Nae Hee; Koh, Kwang Kon; Kang, Tae Soo; Jo, Sang Ho; Hong, Bum Kee; Bae, Jang Ho; Yang, Hyoung Mo; Cha, Kwang Soo; Kim, Bum Soo; Kwak, Choong Hwan; Cho, Deok Kyu; Kim, Ung; Zo, Joo Hee; Kang, Duk Hyun; Pyun, Wook Bum; Chun, Kook Jin; Namgung, June; Cha, Tae Joon; Juhn, Jae Hyeon; Jung, Yeili; Jang, Yangsoo.

In: Korean Circulation Journal, Vol. 45, No. 3, 01.05.2015, p. 225-233.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients

AU - Jang, Ji Yong

AU - Lee, Sang Hak

AU - Kim, Byung Soo

AU - Seo, Hong Seog

AU - Kim, Woo Shik

AU - Ahn, Youngkeun

AU - Lee, Nae Hee

AU - Koh, Kwang Kon

AU - Kang, Tae Soo

AU - Jo, Sang Ho

AU - Hong, Bum Kee

AU - Bae, Jang Ho

AU - Yang, Hyoung Mo

AU - Cha, Kwang Soo

AU - Kim, Bum Soo

AU - Kwak, Choong Hwan

AU - Cho, Deok Kyu

AU - Kim, Ung

AU - Zo, Joo Hee

AU - Kang, Duk Hyun

AU - Pyun, Wook Bum

AU - Chun, Kook Jin

AU - Namgung, June

AU - Cha, Tae Joon

AU - Juhn, Jae Hyeon

AU - Jung, Yeili

AU - Jang, Yangsoo

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background and Objectives: We compared the efficacy and safety of valsartan and rosuvastatin combination therapy with each treatment alone in hypercholesterolemic hypertensive patients. Subjects and Methods: Patients who met inclusion criteria were randomized to receive 1 of the following 2-month drug regimens: valsartan 160 mg plus rosuvastatin 20 mg, valsartan 160 mg plus placebo, or rosuvastatin 20 mg plus placebo. The primary efficacy variables were change in sitting diastolic blood pressure (sitDBP) and sitting systolic blood pressure (sitSBP), and percentage change in low-density lipoprotein-cholesterol (LDL-C) in the combination, valsartan, and rosuvastatin groups. Adverse events (AEs) during the study were analyzed. Results: A total of 354 patients were screened and 123 of them were finally randomized. Changes of sitDBP by least squares mean (LSM) were -11.1, -7.2, and -3.6 mm Hg, respectively, and was greater in the combination, as compared to both valsartan (p=0.02) and rosuvastatin (p<0.001). Changes of sitSBP by LSM were -13.2, -10.8, and -4.9 mm Hg, and was greater in the combination, as compared to rosuvastatin (p=0.006) and not valsartan (p=0.42). Percentage changes of LDL-C by LSM were -52, -4, and -47% in each group, and was greater in the combination, as compared to valsartan (p<0.001), similar to rosuvastatin (p=0.16). Most AEs were mild and resolved by the end of the study. Conclusion: Combination treatment with valsartan and rosuvastatin exhibited an additive blood pressure-lowering effect with acceptable tolerability, as compared to valsartan monotherapy. Its lipid lowering effect was similar to rosuvatatin monotherapy.

AB - Background and Objectives: We compared the efficacy and safety of valsartan and rosuvastatin combination therapy with each treatment alone in hypercholesterolemic hypertensive patients. Subjects and Methods: Patients who met inclusion criteria were randomized to receive 1 of the following 2-month drug regimens: valsartan 160 mg plus rosuvastatin 20 mg, valsartan 160 mg plus placebo, or rosuvastatin 20 mg plus placebo. The primary efficacy variables were change in sitting diastolic blood pressure (sitDBP) and sitting systolic blood pressure (sitSBP), and percentage change in low-density lipoprotein-cholesterol (LDL-C) in the combination, valsartan, and rosuvastatin groups. Adverse events (AEs) during the study were analyzed. Results: A total of 354 patients were screened and 123 of them were finally randomized. Changes of sitDBP by least squares mean (LSM) were -11.1, -7.2, and -3.6 mm Hg, respectively, and was greater in the combination, as compared to both valsartan (p=0.02) and rosuvastatin (p<0.001). Changes of sitSBP by LSM were -13.2, -10.8, and -4.9 mm Hg, and was greater in the combination, as compared to rosuvastatin (p=0.006) and not valsartan (p=0.42). Percentage changes of LDL-C by LSM were -52, -4, and -47% in each group, and was greater in the combination, as compared to valsartan (p<0.001), similar to rosuvastatin (p=0.16). Most AEs were mild and resolved by the end of the study. Conclusion: Combination treatment with valsartan and rosuvastatin exhibited an additive blood pressure-lowering effect with acceptable tolerability, as compared to valsartan monotherapy. Its lipid lowering effect was similar to rosuvatatin monotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84930399492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930399492&partnerID=8YFLogxK

U2 - 10.4070/kcj.2015.45.3.225

DO - 10.4070/kcj.2015.45.3.225

M3 - Article

AN - SCOPUS:84930399492

VL - 45

SP - 225

EP - 233

JO - Korean Circulation Journal

JF - Korean Circulation Journal

SN - 1738-5520

IS - 3

ER -